Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma

Bone Marrow Transplantation

Volumn 41, Issue 10, 2008, Pages 867-872

  Gardner, S L ^a   Carreras, J ^b   Boudreau, C ^c   Camitta, B M ^b   Adams, R H ^d   Chen, A R ^e   Davies, S M ^f   Edwards, J R ^g   Grovas, A C ^h   Hale, G A ⁱ   Lazarus, H M ^j   Arora, M ^k   Stiff, P J ^l   Eapen, M ^b  

^a NEW YORK UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF WATERLOO   (Canada)

^d MAYO CLINIC   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^h UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

ⁱ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^j UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

^l LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; MELPHALAN;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER GROWTH; CANCER LOCALIZATION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EWING SARCOMA; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; ORTHOPEDIC SURGERY; OVERALL SURVIVAL; PATIENT ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT CANCER; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; CHILD; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; RISK FACTORS; SARCOMA, EWING'S; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 44449153972     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.2     Document Type: Article

References (23)

1. Ginsberg JP, Woo SY, Johnson ME, Hicks MJ, Horowitz ME. Ewing's sarcoma family of tumors: Ewing's sarcoma of bone soft tissue and the peripheral primitive neuroectodermal tumors. In: Pizzo and Poplack. Lippincott Williams and Wilkins: Philadelphia, PA, 2002, pp 973-1016.
2. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348: 694-701.
3. Cangir A, Vietti TJ, Gehan EA, Burgett Jr EO, Thomas P, Tefft M et al Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990; 66: 887-893.
4. Miser JS, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: Evaluation of combination ifosfamide and etoposide - A Children's Cancer Group and Pediatric Oncology Group Study. J Clin Oncol 2004; 22: 2873-2876.
5. Paulussen M, Ahrens S, Craft AW, Dunst J, Frohlich B, Jabar S et al Ewing's tumors with primary lung metastases: Survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998; 16: 3044-3052.
6. Shankar AG, Ashley S, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003; 40: 141-147.
7. Rodriguez-Galindo C, Billups CA, Kun LE, Rao BN, Pratt CB, Merchant TE et al. Survival after recurrence of Ewing tumors: The St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002: 94: 561-569.
8. Ahrens S, Hoffmann C, Jabar S, Braun-Munzinger G, Paulussen M, Dunst J et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: The CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol 1999; 32: 186-195.
9. Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH et al The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998; 80: 1020-1033.
10. de Alava E, Kawai A, Healey JH, Fligman I, Meyers PA, Huvos AG et al EWS-FL11 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 1998; 16: 1248-1255.
11. Zoubek A, Dockhorn-Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer-Menz I et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996; 14: 1245-1251.
12. Burdach S, Jurgens H, Peters C, Nurnberger W, Mauz-Korholz C, Korholz D et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11 1482-1488.
13. Fraser CJ, Weigel BJ, Perentesis JP, Dusenbery KE, DeFor TE, Baker KS et al. Autologous stem cell transplantation for high-risk Ewing's sarcoma and other pediatric solid tumors. Bone Marrow Transplant 2006; 37: 175-181.
14. Drabko K, Zawitkowska-Klaczynska J, Wojcik B, Choma M, Zaucha-Prazmo A, Kowalczyk J et al. Mega chemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma. Pediatr Transplant 2005; 9: 618-621.
15. Atra A, Whelan JS, Calvagna V, Shankar AG, Ashley S, Shepherd V et al High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997; 20: 843-846.
16. Ladenstein R, Lasset C, Pinkerton R, Zucker JM, Peters C, Burdach S et al. Impact of mega therapy in children with high-risk Ewing's tumours in complete remission: A report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995; 15: 697-705.
17. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant 2001; 28 1001-1011.
18. Kaplan E. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
19. Cox DR. Regression models and life tables. J R Stat Soc 1972; 34: 187.
20. Therneau T, Grambasch P. Modeling Survival Data: Extending the Cox Model. Springer Verlag: New York. NY, 2000.
21. Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: A Monte Carlo comparison of fixed and random effects tests. Stat Med 1999; 18: 1489-1500.
22. Horowitz ME, Kinsella TJ, Wexler LH, Belasco J, Triche T, Tsokos M et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993; 11: 1911-1918.
23. Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS et al High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001; 19: 2812-2820.